Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, Oct. 29, 2026/ PRNewswire/-- Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, today announced the pricing of its upsized initial public offering of 10,555,555 shares of its common stock at a public offering…